Pulse Biosciences, Inc (NASDAQ:PLSE) Stock Has Consensus Price Target of $50.20

Shares of Pulse Biosciences, Inc (NASDAQ:PLSE) have earned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $53.20.

PLSE has been the subject of a number of recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Friday, July 17th. Oppenheimer restated an “outperform” rating on shares of Pulse Biosciences in a report on Tuesday, July 28th. Mizuho set a $45.00 price target on shares of Pulse Biosciences in a research note on Monday, August 10th. Freedom Capital upgraded shares of Pulse Biosciences to a “strong-buy” rating in a report on Wednesday, September 9th. Finally, Canaccord Genuity Group boosted their price objective on shares of Pulse Biosciences from $43.00 to $58.00 and gave the company a “buy” rating in a research report on Tuesday.

Insider Transactions at Pulse Biosciences

In other news, COO Liane Teplitsky bought 1,001 shares of the stock in a transaction on Tuesday, September 1st. The stock was purchased at an average cost of $49.95 per share, with a total value of $49,999.95. Following the purchase, the chief operating officer owned 4,095 shares of the company’s stock, valued at approximately $204,545.25. The trade was a 32.35% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Insiders have purchased a total of 4,095 shares of company stock worth $199,931 in the last quarter. 74.00% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Osterweis Capital Management Inc. acquired a new stake in shares of Pulse Biosciences during the second quarter worth $28,000. Jupiter Topco LLC acquired a new position in Pulse Biosciences in the second quarter valued at $241,000. GSA Capital Partners LLP acquired a new position in Pulse Biosciences in the second quarter valued at $290,000. Cetera Investment Advisers purchased a new position in Pulse Biosciences during the first quarter worth about $387,000. Finally, Legal & General Group Plc purchased a new position in Pulse Biosciences during the second quarter worth about $395,000. 76.95% of the stock is currently owned by institutional investors and hedge funds.

Pulse Biosciences Price Performance

Shares of Pulse Biosciences stock opened at $53.81 on Tuesday. The business has a 50 day moving average price of $48.96 and a 200 day moving average price of $33.41. The company has a market capitalization of $3.81 billion, a P/E ratio of -45.60 and a beta of 1.57. Pulse Biosciences has a 1 year low of $12.56 and a 1 year high of $58.90.

Pulse Biosciences (NASDAQ:PLSE) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.07). Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%. The company had revenue of $0.43 million during the quarter, compared to analyst estimates of $0.53 million. As a group, research analysts expect that Pulse Biosciences will post -1.29 EPS for the current fiscal year.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a medical technology company developing bioelectric therapies based on its proprietary Nano-Pulse Stimulation (NPS) technology. The platform delivers short, nonthermal electrical pulses that temporarily affect cell membranes and are designed to selectively target unwanted cells while preserving surrounding tissue.

The company’s lead commercial product is the CellFX System, a dermatology platform designed to treat certain benign skin lesions and other dermatologic conditions using NPS technology.